financetom
Business
financetom
/
Business
/
Nutanix Q1 Results Offset By Slowing Annual Recurring Revenue, Federal Vertical Weakness: Analysts
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Nutanix Q1 Results Offset By Slowing Annual Recurring Revenue, Federal Vertical Weakness: Analysts
Nov 27, 2024 11:39 AM

Nutanix, Inc. ( NTNX ) shares are trading lower on Wednesday. The company’s annual recurring revenue grew 18%, while revenue jumped 16%.

Needham analyst Mike Cikos reiterated the Buy rating on Nutanix ( NTNX ), raising the price forecast to $90 from $80. He raised the fiscal 2025 estimate from $1.36 to $1.42.

Cikos highlights that Nutanix’s early success with new go-to-market partnerships and share gains from M&A disruption contributed to strong results in the first quarter of fiscal 2025.

Despite revenue guidance being above projections for the second quarter of fiscal 2025, management kept its outlook unchanged, which the analyst views as a conservative approach.

Cikos also notes Nutanix’s strong track record in setting expectations. Operating margin expansion provides flexibility for continued investment in sales and marketing and R&D, he added.

Also Read: US–Mexico Trade Tensions Escalate As Mexican Peso Hits August 2022 Lows: Why Is Auto Industry Most At Risk?

Northland Capital Markets analyst Nehal Chokshi reiterated the Market Perform rating on Nutanix ( NTNX ), raising the price forecast to $77 from $74.

The analyst notes that Nutanix ( NTNX ) added 630 customers in the quarter — a 66% year-over-year increase. This indicated a re-acceleration in customer acquisition after a three-year lull.

This growth is attributed to a focus on SMBs and the impact of Broadcom Inc. ( AVGO )‘s purchase of VMW .

Despite strong revenue, operating profit, and free cash flow results, the analyst observes a slowdown in annual recurring revenue (ARR) growth to 18% year-over-year, down from 22% in the previous quarter.

The weak incremental ARR of $58 million, a 43% year-over-year decline, is primarily driven by underperformance in the federal vertical, linked to delayed government spending resolutions.

Additionally, the analyst suggests that the elongation of large deals is contributing to the disappointing drop in incremental ARR, as reflected in the deterioration of NRR from 123% in fiscal 2023 to 110% in the first quarter of 2025.

Price Action: NTNX shares are trading lower by 7.17% to $67.18 at last check Wednesday.

Read Now:

Trump's Tariff Plan Targets Imports: Electronics, Retail Stocks At Risk

Image: Shutterstock

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Japan's union group Rengo announces biggest wage hikes on record
Japan's union group Rengo announces biggest wage hikes on record
Mar 22, 2024
TOKYO (Reuters) -Japanese firms have agreed to raise pay by 5.25% this year, the biggest rise under comparable data since 2013, the country's largest union group Rengo confirmed on Friday. The results of the closely-watched wage negotiations are announced in several stages, in which the blue-chip firms are first to wrap up their talks in mid-March. The second announcement on...
Once a beacon of stability, Vietnam to name third president in a year
Once a beacon of stability, Vietnam to name third president in a year
Mar 22, 2024
HANOI, March 22 (Reuters) - Communist-ruled Vietnam is seeking its third president in little more than a year after the resignation of Vo Van Thuong, who was only elected last year after the sudden dismissal of his predecessor. With accumulated foreign direct investment higher than its gross domestic product, Vietnam's stability is crucial to multinationals with large operations in the...
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Mar 22, 2024
05:04 AM EDT, 03/22/2024 (MT Newswires) -- Hutchmed ( HCM ) said late Thursday it has started the registration stage for a phase 2/3 clinical trial of investigational drug sovleplenib for adult patients with warm antibody autoimmune hemolytic anemia in China. The move follows positive data from the proof-of-concept phase 2 stage of the trial and a consultation with the...
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Mar 22, 2024
(Reuters) - Popular investor Cathie Wood's ARK Invest bought nearly 10,000 shares of Reddit ( RDDT ) in the social media platform's strong market debut on Thursday, an email from the asset manager showed. A total of 9,982 shares of the loss-making company was added to ARK Next Generation Internet ETF ( ARKW ) and ARK Fintech Innovation ETF (...
Copyright 2023-2026 - www.financetom.com All Rights Reserved